ResveratrolvsTretinoin

Resveratrol activates SIRT1 (sirtuin 1), a NAD+-dependent deacetylase that deacetylates histones and non-histone targets including p53, FOXO transcription factors, and NF-κB, regulating cellular stress response, DNA repair, autophagy, and inflammatory pathways in keratinocytes and fibroblasts. It scavenges superoxide anion, hydroxyl radical, and metal-induced free radicals through its phenolic hydroxyl groups. Resveratrol inhibits NF-κB nuclear translocation and downstream cytokine production (TNF-α, IL-1β, IL-6), reducing UV-induced inflammation. It inhibits tyrosinase (mild brightening), matrix metalloproteinase-9 (MMP-9, gelatinase B) to prevent collagen and elastin breakdown, and AP-1 (c-Fos/c-Jun) to reduce photoaging-related gene expression. It may also activate Nrf2, upregulating antioxidant enzymes (HO-1, NQO1). Topical application achieves higher skin tissue concentrations than oral supplementation due to first-pass metabolism. Stability is improved in anhydrous or encapsulated formulations.

Tretinoin binds nuclear retinoic acid receptors (RAR-alpha, beta, gamma), forming RAR/RXR heterodimers that bind retinoic acid response elements and activate gene transcription. This accelerates keratinocyte proliferation, reducing stratum corneum transit from ~28 to ~14 days. In the dermis, tretinoin stimulates fibroblasts and upregulates collagen I and III via TGF-beta while downregulating MMP-1, MMP-3, and MMP-9 that degrade the extracellular matrix. It normalizes melanocyte distribution and melanosome transfer. In acne, it prevents microcomedo formation by normalizing follicular keratinocyte differentiation and reducing corneocyte cohesion. RAR activation also modulates genes for epidermal growth factors and differentiation markers.